REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$972.10
Updated
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$907.32 |
52 Week High | US$998.33 |
52 Week Low | US$684.81 |
Beta | 0.14 |
1 Month Change | -5.59% |
3 Month Change | -4.38% |
1 Year Change | 16.62% |
3 Year Change | 86.01% |
5 Year Change | 166.24% |
Change since IPO | 4,195.01% |
Recent News & Updates
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Recent updates
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Oct 25Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price
Aug 07Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet
Jul 17Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Apr 17Shareholder Returns
REGN | US Biotechs | US Market | |
---|---|---|---|
7D | 0.7% | 1.5% | 1.2% |
1Y | 16.6% | 1.1% | 24.7% |
Return vs Industry: REGN exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: REGN underperformed the US Market which returned 24.7% over the past year.
Price Volatility
REGN volatility | |
---|---|
REGN Average Weekly Movement | 2.0% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months.
Volatility Over Time: REGN's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 13,450 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
REGN fundamental statistics | |
---|---|
Market cap | US$97.50b |
Earnings (TTM) | US$3.95b |
Revenue (TTM) | US$13.12b |
24.7x
P/E Ratio7.4x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REGN income statement (TTM) | |
---|---|
Revenue | US$13.12b |
Cost of Revenue | US$6.25b |
Gross Profit | US$6.86b |
Other Expenses | US$2.91b |
Earnings | US$3.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 36.79 |
Gross Margin | 52.32% |
Net Profit Margin | 30.14% |
Debt/Equity Ratio | 7.6% |
How did REGN perform over the long term?
See historical performance and comparison